financetom
Business
financetom
/
Business
/
US FDA staff flags risk of low blood sugar for Novo Nordisk's weekly insulin
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
US FDA staff flags risk of low blood sugar for Novo Nordisk's weekly insulin
May 22, 2024 6:42 AM

May 22 (Reuters) - The U.S. Food and Drug

Administration's (FDA) staff on Wednesday pointed to "notable

imbalance" in incidence of low blood sugar in patients with type

1 diabetes treated with Danish drugmaker Novo Nordisk's

long-acting weekly insulin.

A panel of independent FDA advisers will meet on Friday to

review and discuss the safety and effectiveness of Novo's

insulin, icodec - an under-the-skin injection.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved